In both AKI and ESRD, despite decades of improvements in the provision of renal replacement therapy, the morbidity and mortality rates associated with these disease states have remained largely unaltered. Conventional renal replacement therapies treat volume overload, uremia, acidosis, and electrolyte derangements but have no direct effect on the immune dysregulation that frequently attends AKI and ESRD [7] . Inflammatory cascades initiated by endothelial dysfunction in systemic inflammatory response syndrome are further dysregulated in the setting of AKI, as suggested by recent data that demonstrate that the levels of the proinflammatory cytokines IL-6 and IL-8 in the plasma predict mortality in patients with AKI [8, 9] . Furthermore, strategies that modulate the inflammatory response provide significant beneficial effects in experimental AKI [10] .
Thus, improved therapeutic devices have to be developed with the capacity to replace a wider range of kidney functions, thereby reducing morbidity, mortality, and the overall economic impact associated with AKI and ESRD. The purpose of this review is to describe promising cellbased approaches to mitigating the inflammation that accompanies acute and chronic kidney dysfunction [11] . Cell-based approaches in this review will focus on two broad categories: cell therapy and cell processing. Cell therapy relies on isolated cell populations that are cultured outside of the body and reintroduced during therapy, whereas the cell processing approach seeks to alter a cell population inside the body.
Cell Therapy
To date, the treatment of acute and chronic kidney diseases by cell therapy has been dependent on the development of robust stem cell sources. Stem cells are characterized by their capacity for self-renewal and ability to differentiate into specialized cell types. For an in-depth treatment of the stem cells used for renal applications, see Pino and Humes [12] . Also see reviews on putative resident progenitor/stem cells of the kidney [13] [14] [15] [16] .
In brief, a number of different stem cell sources have been explored for renal disease applications, including embryonic stem cells, induced pluripotent stem cells, and adult stem cells, either from mesenchymal stem cell or renal epithelial progenitor sources. Embryonic stem cell and induced pluripotent stem cell approaches currently have substantive safety and regulatory issues not completely understood or evaluated. Therefore, in this review, cell-based therapies for the treatment of renal disease will focus on adult stem cell treatments. The two main modes of administration for cell-based therapy are direct injection and tissue engineering approaches. Direct injection relies on the inherent capabilities of stem cells to differentiate, organize, and integrate into existing tissues to restore function. Tissue engineering approaches are based on in vitro differentiation of stem cells on biomaterial scaffolds, which are then applied in vivo or ex vivo to provide therapy. This will be the focus of this review.
Tissue Engineering Approach to Renal Progenitor Therapies
Tissue engineering involves the in vitro manipulation of cells applied to biomaterials, which may be biodegradable or permanent substrates for cell attachment, to produce a device for implantation or incorporation into an extracorporeal circuit. Cell therapy with a single differentiated cell type to replace a specific metabolic or catabolic function is currently in practice [12] . However, the biotechnology tools required to fabricate a complete, functioning organ for transplantation are still in their infancy.
The strategy adopted by Humes and colleagues [8, 17] has been to administer cell therapy from an extracorporeal circuit, allowing for immunoisolation of a cell device, eliminating immunorejection issues, and enabling the use of allogeneic cells. In brief, this strategy utilized hemofiltration as a working substitute for glomerular filtration, with metabolic and synthetic functions of proximal tubule cells replaced through the application of a renal tubule assist device (RAD). The RAD consisted of primary renal cells, isolated and expanded from adult kidneys in vitro [18, 19] , that were seeded on the inner surface of a hemofilter with polysulfone hollow fibers [17, 20, 21] . Cell attachment was promoted by collagen type IV [22] . In vitro testing of the RAD demonstrated differentiated renal tubule cell function including active transport, renal cell-specific metabolic activity, and endocrine secretion [22] .
In ex vivo animal testing, RADs containing either porcine or human cells were evaluated on uremic dogs following bilateral nephrectomy. Improvements in multiple physiological parameters were observed in RADtreated animals compared to acellular RAD controls [22, 23] . Furthermore, in canine and porcine models of AKI with septic shock, RAD treatment was shown to modulate plasma cytokine levels, maintain better car-diovascular performance, and increase survival times [22, 24] .
Promising preclinical studies prompted an initial phase I/II FDA clinical trial of RAD treatment of 10 critically ill patients with AKI and MOF receiving continuous venovenous hemofiltration [25] . The results from this study demonstrated that RAD therapy was safe for use for up to 24 h and that the cell device retains viability, durability, and functionality throughout therapy [25] . In a phase II randomized, controlled, open-label trial, involving 58 patients with AKI at 12 clinical sites, RAD treatment promoted a statistically significant survival advantage (33% mortality at day 28) over patients treated by conventional continuous venovenous hemofiltration (61% mortality at day 28) [26] .
During a follow-up phase IIb study to evaluate a commercial manufacturing process for the RAD, the clinical study was suspended after an interim analysis revealed an unanticipated high survival rate of patients treated with sham control RAD without cells [27] . These findings with the RAD led to 2 separate therapy approaches: one device approach without cells called the selective cytopheretic device (SCD) (discussed in further detail below, under Cell Processing Approach), and a new cell-based device called the bioartificial renal epithelial cell system (BRECS), designed from the insight provided by the phase IIb study. The phase IIb study exposed the fact that production and distribution of RADs would be a major obstacle in the widespread adoption of renal cell therapy. In response, an engineered solution was initiated through the development of a cell system that would be cryopreservable, to enable distribution, storage, and therapeutic use at point-of-care facilities. Cryopreservation of biological samples and tissue engineering constructs have been widely recognized as an obstacle to the practical implementation of regenerative medicine [28] . The BRECS was developed with the intent to be cryopreserved; a device which functions as a combined bioreactor, cryostorage device, and cell therapy delivery system. Briefly, porous, niobium-coated carbon disks were used as cell scaffolds within the BRECS, and culture media was perfused through and around the porous disks. A recently developed technique of expanded propagation allowed for the amplification of kidney progenitor cells from human kidney tissue procured from National Disease Research Interchange (Philadelphia, Pa., USA), to serve as a robust therapeutic cell source for seeding BRECS. Application of the defined expanded propagation method resulted in an increase of up to 8 orders of magnitude in cell yield over historic, standard propagation techniques [29] . In vitro measurements of glucose and oxygen consumption, lactate generation, and glutathione degradation suggest the maintenance of more than 1 ! 10 8 cells in each BRECS during up to 5 months in culture [30] . Ex vivo large animal studies suggest that utilizing the BRECS in conjunction with standard hemofiltration is a promising approach to treat both AKI and ESRD [30] [31] [32] .
Cell Processing Approach
In a retrospective analysis of the phase IIb RAD study, paying particular attention to sham control RAD groups, the improved survival rate for acellular RAD treatment was demonstrated only when regional citrate anticoagulation was utilized in additional to systemic heparinization, and not when only systemic heparin anticoagulation was used. Patients treated with the acellular RAD had a mortality rate of 50% if treated with heparin versus 25% if treated with citrate (n = 12 for each treatment arm) at 28 days and 75 versus 33% at 90 days ( 2 ! 0.05) [27] . The subgroups were comparable with respect to sequential organ failure assessment scores, organ failure number, and incidence of sepsis.
Subsequent studies focused on understanding the mechanism of action by this noncellular, RAD hemofilter during regional citrate anticoagulation. It was hypothesized that the observed improvement in patient survival was mediated by a stabilizing effect that the acellular filter had, specifically conferred in a low-ionized calcium environment created by citrate administration in the blood circuit [33, 34] . Immunofluorescence microscopy of the sham cartridges after patient treatment demonstrated adherent leukocytes on the outer surface of the membranes of the cartridge along the blood flow path within the extracorporeal circuit [27] . The sequestered leukocytes were dominated by neutrophils. The ability of leukocytes to bind to the outer walls of the hollow fiber membranes rather than the inner walls, which is the conventional blood flow path, was recognized to be due to the low shear forces of blood flow. The shear stress of blood along the outer wall of the membrane was near capillary shear stress of ! 1 dyn/cm 2 compared to the shear stress of nearly 100 dyn/cm 2 of blood when flowing along the inner conventional surfaces of the hollow fiber membranes. The role of citrate infusion in this device related to the effect of citrate to lower the ionized calcium levels of blood to below 0.4 m M , a level which inhibits the coagulation system of blood. This lower ionized calcium level also has an inhibitory effect on neutrophil activation [35] , resulting in a simultaneous combination effect to sequester activated circulating leukocytes and alter the activity of the bound leukocytes. Further studies now suggest that the bound leukocytes may be subsequently released back to the systemic circulation in an altered apoptotic state. Consequently, the membrane cartridge is referred to as an SCD due to its ability to sequester cells, and in the presence of citrate anticoagulation, the SCD is an immunomodulatory device.
The SCD was further tested in a septic shock porcine model where SCD efficacy was evaluated treating AKI associated with septic shock caused by administering Escherichia coli into the peritoneum of pigs [24] . This septic shock model demonstrated that the SCD treatment lowers neutrophil activity (serum myeloperoxidase and CD11b cell surface expression), diminishes neutrophil tissue invasion, decreases systemic capillary leak, preserves cardiac output and mean arterial pressure, and prolongs survival time [35] . The SCD was also tested in a bovine model of cardiopulmonary bypass, and similarly showed decreased numbers of leukocytes throughout SCD therapy [36] . Further experiments have suggested that the 'catch and release' of activated neutrophils within the SCD [35] promoted the activated neutrophil to enter a delayed apoptotic state. This observation is consistent with previous work that demonstrated that blocking calcium entry into a neutrophil activates the apoptotic pathway to programmed cell death [37] .
With these favorable animal studies confirming the early mechanistic observations from the RAD study, the evaluation of the SCD with citrate anticoagulation has continued in two exploratory pilot clinical trials in intensive care unit (ICU) patients with AKI and MOF. This patient group was chosen due to the ease of incorporating this device into the standard continuous renal replacement therapy (CRRT) blood circuit during treatment of these critically ill patients ( fig. 1 ). These early exploratory clinical trials have demonstrated an excellent safety profile and compelling efficacy impact [27, 38, 39] . Leukopenia and sustained thrombocytopenia were not observed in these clinical studies. Accelerated renal recovery with CRRT discontinuation and an approximately 50% or greater relative improvement in survival rates have been observed. SCD-CRRT circuit diagram depicting regional citrate anticoagulation. Citrate is administered before SCD, and ionized calcium is replaced after SCD, prior to blood return to the patient. A prospective, single-arm, single-center clinical study was conducted to evaluate the safety and efficacy of the SCD in a dose-ranging study in ICU patients with AKI and MOF [38] . This study was approved by the local institutional review board as a nonsignificant risk designation. The dose-ranging study included increasing the effective outer membrane surface area from 1.0 to 1.4 m 2 and by increasing SCD treatment from 72 h up to 7 days with SCD replacement every 24 h. Nine patients were enrolled in the trial and were compared with historical casematched controls with respect to age and sequential organ failure assessment score utilizing the PICARD/NIH database [40] . The mortality rate for the case-matched controls was 78%, while the mortality in the SCD treatment group was 22% (p = 0.027). Multiple regression analysis identified treatment with SCD as the only significant variable affecting mortality. Mean total urine output in the patients receiving SCD treatment increased from a baseline of approximately 500 ml/day to more than 2,000 ml/day by day 7 of treatment as opposed to historical case-matched controls, whose urine output decreased with time ( fig. 2 ) . In fact, in the last 5 patients receiving the larger SCD membrane renal function and urine output were improved after 72 h so that no dialytic treatment was necessary after 3 days. Once again, treatment with SCD was well tolerated, without significant effects on hematological parameters, and with an adverse event profile expected for a seriously ill population in the ICU with AKI. The blood flow patency of the SCD was comparable with single-cartridge CRRT modalities. These results suggested a higher dose with a larger membrane surface area, and longer treatment time was safe and potentially more effective.
A US multicenter pilot clinical study was conducted to assess the safety and efficacy of the SCD in ICU patients with acute renal failure and MOF [39, 41] . This study was undertaken with an FDA-approved investigational device exemption (G090189). A total of 35 patients at 6 clinical sites were enrolled (ClinicalTrials.gov, ID No. NCT01072682). Those 35 patients had an average age of 56 years, an average sequential organ failure assessment score of 11.5 and 28/35 (80%) patients were septic. Ninety percent (31/35) of the patients were on mechanical ventilation. For the entire patient group, 28-day all-cause mortality was 20% and 60-day all-cause mortality was 31%. For the septic patients, 28-day and 60-day all-cause mortality rates were similar to those of the entire patient group outcomes. This compared favorably to historical conventional renal replacement therapy mortality rates exceeding 50% ( fig. 3 ). There were no SCD-treated patients requiring dialysis at 60 days compared to 8% in the comparative control group.
Conclusion
Conventional treatment of acute and chronic renal diseases has focused on solute removal. Novel strategies aim to treat the multifactorial disease states of AKI and chronic kidney disease by mitigating inflammation using cell therapy or cell processing approaches. Cell therapy leverages the metabolic and synthetic functions of renal tubule cells to provide gluconeogenesis, ammoniagenesis, metabolism of glutathione, catabolism of important peptide hormones, growth factors, and cytokines critical to multiorgan homeostasis and immunomodulation. A cell processing approach utilizing a promising, new therapeutic device -the SCD -is designed to address the proinflammatory state of kidney dysfunction by binding and deactivating leukocytes.
